Fatty Acid Synthase (C20G5) Rabbit mAb产品图

Fatty Acid Synthase (C20G5) Ra

bbit mAb
收藏
  • 询价
  • Cell Signaling Technology已认证
  • USA
  • 2026年05月29日
  • W, IP, IHC-P, IHC-F, IF-IC
  • H,M,R,B
avatar
品牌商
13钻石会员
  • 企业认证

    • 详细信息
    • 文献和实验
    • 技术资料
    • 抗体英文名

      Fatty Acid Synthase (C20G5) Rabbit mAb

    • 抗原

      synthetic peptide around Gly46 corresponding to the sequence of human fatty acid synthase

    • 应用范围

      W, IP, IHC-P, IHC-F, IF-IC

    • 级别

      详见MSDS文件

    • 供应商

      CST

    • 适应物种

      H,M,R,B

    • 库存

      大量

    • 保质期

      详见说明书

    • 是否单克隆

      0

    • 保存条件

      -20°c

    • 规格

      100 ul (10 western blots)/carrier free & custom formulation / quantity

    规格:产品价格:¥请询价
    规格:100 ul (10 western blots)产品价格:¥请询价
    规格:carrier free & custom formulation / quantity产品价格:¥请询价

    pathway more info application references datasheet PDF MSDS PDF protocols

    Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IHC-P=Immunohistochemistry (Paraffin)  IHC-F=Immunohistochemistry (Frozen)  IF-IC=Immunofluorescence (Immunocytochemistry)
    Reactivity Key:  H=Human  M=Mouse  R=Rat  B=Bovine
    Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

    Applications Reactivity Sensitivity MW (kDa) Isotype
    W IP IHC-P IHC-F IF-IC H M R (B) Endogenous 273 Rabbit IgG
    Protocols
    Specificity / Sensitivity

    Fatty Acid Synthase (C20G5) Rabbit mAb detects endogenous levels of total fatty acid synthase protein.

    Source / Purification

    Fatty Acid Synthase (C20G5) Rabbit mAb is produced by immunizing rabbits with a synthetic peptide around Gly46 corresponding to the sequence of human fatty acid synthase.

    Western Blotting

    Western Blotting

    Western blot analysis of extracts from various cell types using Fatty Acid Synthase (C20G5) Rabbit mAb.

    IHC-P (paraffin)

    IHC-P (paraffin)

    Immunohistochemical analysis of paraffin-embedded breast carcinoma using Fatty Acid Synthase (C20G5) Rabbit mAb.

    IHC-P (paraffin)

    IHC-P (paraffin)

    Immunohistochemical analysis of paraffin-embedded hepatocellular carcinoma using Fatty Acid Synthase (C20G5) Rabbit mAb.


    IHC-P (paraffin)

    IHC-P (paraffin)

    Immunohistochemical analysis of paraffin-embedded lung carcinoma using Fatty Acid Synthase (C20G5) Rabbit mAb.

    IHC-P (paraffin)

    IHC-P (paraffin)

    Immunohistochemical analysis of paraffin-embedded lymphoma, showing staining of adipocytes, using Fatty Acid Synthase (C20G5) Rabbit mAb.

    IHC-P (paraffin)

    IHC-P (paraffin)

    Immunohistochemical analysis of paraffin-embedded mouse brown fat using Fatty Acid Synthase (C20G5) Rabbit mAb.


    IHC-F (frozen)

    IHC-F (frozen)

    Immunohistochemical analysis of frozen SKOV-3 xenograft using Fatty Acid Synthase (C20G5) Rabbit mAb.

    IF-IC

    IF-IC

    Confocal immunofluorescent analysis of HeLa cells using Fatty Acid Synthase (C20G5) Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5™ (fluorescent DNA dye).

    Background

    Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1).Recently, increased expression of FASN has emerged as a phenotype common to most human carcinomas. In breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).

    1. Katsurada, A. et al. (1990) Eur J Biochem 190, 427-33.
    2. Wells, W.A. et al. (2006) Breast Cancer Res Treat 98, 231-40.
    3. Kawamura, T. et al. (2005) Pathobiology 72, 233-240.
    4. Shah, U.S. et al. (2006) Hum Pathol 37, 401-409.
    5. Kuhajda, F.P. (2000) Nutrition 16, 202-8.
    6. Tian, W.X. (2006) Curr Med Chem 13, 967-977.
    7. Kusunoki, J. et al. (2006) Endocrine 29, 91-100.
    Application References

    Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know !

    Companion Products

    For Research Use Only. Not For Use In Diagnostic Procedures.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    [1]Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer
    PMID:42436555J Exp Clin Cancer Res2026-07-11
    [2]Bioactive compounds from Sargassum horneri attenuates inflammation and obesity regulating by Nrf2/HO-1 and AMPK signaling pathways.
    PMID:41372250Sci Rep2025-12-10
    [3]Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway.
    PMID:40790070Sci Rep2025-08-11
    [4]A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage.
    PMID:40638641PLoS One2025-07-10
    [5]Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism.
    PMID:40155472J Cancer Res Clin Oncol2025-03-28
    [6]SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase.
    PMID:39825408Lipids Health Dis2025-01-17
    [7]Glycerol Kinase Drives Hepatic de novo Lipogenesis and Triglyceride Synthesis in Nonalcoholic Fatty Liver by Activating SREBP-1c Transcription, Upregulating DGAT1/2 Expression, and Promoting Glycerol Metabolism.
    PMID:39418169Adv Sci (Weinh)2024-12
    [8]USP7- and PRMT5-dependent G3BP2 stabilization drives de novo lipogenesis and tumorigenesis of HNSC.
    PMID:36878903Cell Death Dis2023-03-06
    [9]Mouse promyelocytic leukemia zinc finger protein (PLZF) regulates hepatic lipid and glucose homeostasis dependent on SIRT1.
    PMID:36438786Front Pharmacol2022-11-10
    [10]Obesity treatment by epigallocatechin-3-gallate-regulated bile acid signaling and its enriched Akkermansia muciniphila.
    PMID:29882708FASEB J2018-06
    相关实验
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    美国CST中国公司(丁香通商铺)
    2024年04月07日询价
    询价
    上海谷研实业有限公司
    2026年01月26日询价
    ¥4043
    上海远慕生物科技有限公司
    2025年05月26日询价
    ¥4043
    上海岑特生物科技有限公司
    2025年05月26日询价
    ¥2972
    北京智杰方远科技有限公司
    2025年07月15日询价
    Fatty Acid Synthase (C20G5) Rabbit mAb
    询价